Gossamer Bio Inc (NASDAQ: GOSS) on Friday, plunged -2.13% from the previous trading day, before settling in for the closing price of $0.98. Within the past 52 weeks, GOSS’s price has moved between $0.50 and $1.55.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of -178.50%. With a float of $182.60 million, this company’s outstanding shares have now reached $226.60 million.
Let’s determine the extent of company efficiency that accounts for 145 employees. In terms of profitability, gross margin is 98.28%, operating margin of -52.24%, and the pretax margin is -48.5%.
Gossamer Bio Inc (GOSS) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Gossamer Bio Inc is 19.64%, while institutional ownership is 58.90%. The most recent insider transaction that took place on Jun 24 ’24, was worth 1,260. In this transaction Chief Medical Officer of this company sold 1,908 shares at a rate of $0.66, taking the stock ownership to the 196,891 shares. Before that another transaction happened on Jun 21 ’24, when Company’s President & CEO bought 372,000 for $0.67, making the entire transaction worth $250,282. This insider now owns 5,408,073 shares in total.
Gossamer Bio Inc (GOSS) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.19 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -178.50% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 14.60% during the next five years compared to 40.29% growth over the previous five years of trading.
Gossamer Bio Inc (NASDAQ: GOSS) Trading Performance Indicators
Gossamer Bio Inc (GOSS) is currently performing well based on its current performance indicators. A quick ratio of 6.88 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.90.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.26, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.46 in one year’s time.
Technical Analysis of Gossamer Bio Inc (GOSS)
Looking closely at Gossamer Bio Inc (NASDAQ: GOSS), its last 5-days average volume was 2.06 million, which is a jump from its year-to-date volume of 1.51 million. As of the previous 9 days, the stock’s Stochastic %D was 77.87%. Additionally, its Average True Range was 0.10.
During the past 100 days, Gossamer Bio Inc’s (GOSS) raw stochastic average was set at 33.02%, which indicates a significant decrease from 80.94% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 92.62% in the past 14 days, which was lower than the 94.70% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1337, while its 200-day Moving Average is $0.9749. However, in the short run, Gossamer Bio Inc’s stock first resistance to watch stands at $1.0055. Second resistance stands at $1.0526. The third major resistance level sits at $1.1054. If the price goes on to break the first support level at $0.9056, it is likely to go to the next support level at $0.8528. Now, if the price goes above the second support level, the third support stands at $0.8057.
Gossamer Bio Inc (NASDAQ: GOSS) Key Stats
Market capitalization of the company is 217.75 million based on 227,221K outstanding shares. Right now, sales total 114,700 K and income totals -56,530 K. The company made 9,380 K in profit during its latest quarter, and -33,030 K in sales during its previous quarter.
